Autobio forming a pattern of immunodiagnostic products and microbiological te
Founded in 1999, Antu Biological is specialized in the development, production and sales of in vitro diagnostic reagents and instruments, forming a pattern of immunodiagnostic products and microbiological testing products. The company's products cover a wide range of testing fields from infectious diseases to non-infectious diseases, and can meet the various testing needs of end users. The reagents cover infectious diseases, tumors, reproductive endocrinology, thyroid function, liver fibrosis, eugenics, diabetes, hypertension, heart disease, genitourinary tract diseases, respiratory diseases, bacterial isolation and culture, identification and susceptibility analysis and other testing fields. In addition, the company has always insisted on the joint development of reagents and instruments, and the related equipment covers chemiluminescence immunoassay analyzer, enzyme labeling instrument, plate washer, laboratory analyzer, automatic sample processing system, automatic chemiluminescence analyzer and other products.
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
AI-driven Biotech Galixir Nominates Preclinical Candidate in Treating Autoimmune Disease
Founded in 2019, Galixir named a Preclinical Candidate (PCC) for the treatment of Autoimmune Disease (AID) which was screened out of around 80 compounds via its proprietary platform, Pyxir®, making it another top-ranking China-based AI-driven drug discovery company.
Jun 21, 2022 01:44 PM
Where Will AI Take Drug Discovery in China to?
The development of drug discovery in China is relatively slower than in many other countries but China’s pharma market size is among the top three worldwide. Deeper exploration of drug discovery is much needed in China. AI can make a machine execute tasks like a human or even better than humans. With many emerging AI-powered drug discovery companies in China, can AI help China beat the pioneers in drug discovery at their own game?
Jun 21, 2022 01:19 PM